Application of sapanisertib in preparation of anti-aging medicine

The screening of sapanisertib through the zebrafish Wrn mutant model solved the problem that it was difficult to establish in vertebrate models and achieved efficient screening and verification of anti-aging drugs. Sapanisertib showed significant anti-aging effects in physiologically aged animals, delaying cells and Individual aging.

CN118924762APending Publication Date: 2024-11-12SOUTHWEST UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411210652.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The lack of effective vertebrate models in the prior art has led to the problems of long experimental cycles, difficulty in controlling and lack of suitable biological simulation environments, which affects the drug development process.

Method used

The zebrafish Wrn mutant was used as a premature aging model, and met mutants were identified through ENU forward genetic screening, and it was found that sapanisertib had significant anti-aging effects, which were used to screen anti-aging drugs to further verify its effect in physiologically aged animals.

Benefits of technology

Sapanisertib can effectively resist the accelerated aging phenomenon in animals with Wrn gene deletion, delay cell aging, improve individual lifespan and exercise ability, reduce fatty liver risk and DNA damage, and is suitable for screening and treatment of anti-aging drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924762A_ABST
    Figure CN118924762A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of anti-aging drugs, in particular to application of sapanisertib in preparation of an anti-aging drug. According to the technical scheme, the zebra fish premature senility mutant is obtained through ENU forward genetic screening; the mutation gene of the mutant is determined to be wrn through technologies of localization cloning, gene sequencing and the like, and the gene is related to the Whara syndrome of human. The mutant is used for screening anti-aging drugs, and a drug with the effect of treating premature senility is screened from 2442 compounds. A series of researches show that the medicine can prolong the life of a premature senility individual, reduce lipid accumulation in the liver and reduce DNA (Deoxyribose Nucleic Acid) damage. The medicine also has the effects of resisting physiological senescence (natural senescence), cell replicative senescence and the like. According to the technical scheme, the technical problem that medicines and methods for effectively treating premature senility or delaying physiological senility are lacked in the prior art is solved, and the traditional Chinese medicine composition has ideal popularization and application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of anti-aging drugs, and in particular to the application of sapanisertib in the preparation of anti-aging drugs. Background Art

[0002] With the continuous aging of the population, the development of drug intervention measures to deal with aging and aging-related diseases has become a major challenge that the medical community urgently needs to solve. For related drug development, a large number of in vitro experiments and animal experiments need to be carried out before clinical trials. Among them, the establishment of appropriate animal models is one of the key links to improve the level of drug development. Due to the long lifespan of vertebrates, it is difficult to use vertebrates to establish animal models for the development of anti-aging drugs, which will lead to problems such as long experimental cycles and difficulties in effectively controlling the experimental process. At present, the screening of anti-aging drugs mainly relies on in vitro models or invertebrate models. However, in vitro models cannot fully simulate the complex physiological environment in organisms, and invertebrate models lack key organs and systems in the human aging process. It can be seen that due to the difficulty in effectively establishing a suitable vertebrate aging model, the development of drugs for aging and aging-related diseases faces various problems, which seriously affects the progress of new drug research and development. Summary of the invention

[0003] The present invention is intended to provide the use of sapanisertib in the preparation of anti-aging drugs to solve the technical problem of the lack of drugs and methods for effectively treating premature aging or delaying physiological aging in the prior art.

[0004] In order to achieve the above object, the present invention adopts the following technical scheme:

[0005] Application of sapanisertib in the preparation of anti-aging drugs.

[0006] The principle of adopting the above scheme is that human WRN gene mutation is related to Werner syndrome (WS), which is characterized by accelerated aging of patients, making the animal model related to it an ideal model for studying aging. In order to screen anti-aging drugs in vertebrates, the inventor obtained zebrafish wrn mutants and found that the mutant reproduced many aging characteristics of WS patients. Therefore, the inventor used zebrafish wrn mutants for large-scale drug screening and found that sapanisertib has a significant anti-aging effect. The inventor further applied sapanisertib to physiological aging animals and found that sapanisertib can not only resist the accelerated aging phenomenon in wrn gene-deficient animals, but also resist natural aging, and has an ideal application prospect. In addition, experimental data also proves that the wrn gene-deficient animal model of this scheme is very suitable for screening anti-aging drugs.

[0007] Further, the anti-aging drug is a drug that resists physiological aging or cell replicative aging. In Example 7, sapanisertib treatment increased the cell proliferation capacity of the intestine and kidney medulla of aged zebrafish. In Example 8, a large number of SA-β-Gal signals appeared when HFF cells were passed to the 30th generation (P30), and this phenomenon was reversed after sapanisertib treatment; in addition, sapanisertib increased the proliferation rate of the 30th generation HFF cells.

[0008] Furthermore, the anti-aging drug is a drug for resisting premature aging.

[0009] Further, drugs to combat premature aging are drugs for treating Werner syndrome.

[0010] Further, sapanisertib is used to improve the lifespan and athletic ability of premature aging individuals. In Example 6, sapanisertib has the function of extending the lifespan and healthy lifespan of met mutants. Sapanisertib can be used to improve the lifespan and athletic ability of premature aging individuals.

[0011] Further, sapanisertib is used to reduce the expression level of β-galactosidase, as well as the expression levels of p21 and p53 genes. In Example 3, the quantitative PCR results showed that the expression levels of p21 and p53 were significantly upregulated in the intestine of the mutant, and were significantly inhibited after sapanisertib treatment, indicating that sapanisertib can delay cell aging; SA-β-gal staining results showed that compared with wild-type embryos, a large number of blue signals appeared in the intestine of met mutants, and the blue signals in the mutants after sapanisertib treatment were significantly reduced, further indicating that sapanisertib can effectively delay cell aging.

[0012] Further, sapanisertib is used to reduce the risk of fatty liver in premature individuals. In Example 5, the results of oil red O (ORO) lipid staining and whole embryo in situ hybridization of the fatty liver marker cetp showed that there was more lipid accumulation in the liver of met mutants, and sapanisertib treatment significantly reduced the lipid in the liver.

[0013] Further, sapanisertib is used to reduce DNA damage in premature aging individuals. In Example 6, the number of γH2AX-positive cells in the intestine of met mutants increased significantly, but the level of γH2AX decreased significantly after sapanisertib treatment, indicating that drug treatment reduced the accumulation of DNA damage.

[0014] Furthermore, sapanisertib is used alone or in combination with other pharmacologically active compounds and / or extracts.

[0015] Furthermore, sapanisertib and a pharmaceutically acceptable carrier are prepared into tablets, capsules, granules, powders, oral liquids, syrups or injections.

[0016] In summary, the principle and beneficial effects of this technical solution are:

[0017] The inventors identified a zebrafish premature aging mutant through N-ethyl-N-nitrosourea (ENU) forward genetic screening and named it meteor (met). Through positional cloning and gene sequencing and other technologies, it was found that the mutating gene of the met mutant is wrn. The met mutant can simulate human premature aging symptoms, overcoming the technical problem of difficulty in screening anti-aging drugs due to the lack of a suitable animal model. Therefore, the zebrafish met mutant can be used to efficiently screen anti-aging drugs (Example 1). The met mutant premature aging model has the following characteristics: in the early stages of development, compared with the wild type of the same age, the expression of intestinal β-galactosidase is increased, the expression of the marker genes p21 and p53 of cell aging is increased, the individual lifespan and motor ability are reduced, the lipid accumulation in the liver is increased, and the DNA damage in the body is increased. Compared with general natural aging, the premature aging symptoms represented by Werner syndrome are somewhat different, and the differences include but are not limited to the above situations.

[0018] The inventors further conducted drug screening on 2442 compounds in the above-mentioned met mutant premature aging model and found that sapanisertib has a good anti-premature aging effect. Sapanisertib can reduce the expression of intestinal β-galactosidase, reduce the expression of marker genes p21 and p53 of cell aging, improve individual life span and athletic ability, reduce lipid accumulation in the liver, and reduce DNA damage. Sapanisertib has the above-mentioned multi-faceted functions, which have not been reported in the prior art, and the above-mentioned multiple functions are also the key to the comprehensive treatment of premature aging symptoms represented by Werner syndrome by the small molecule compound. Therefore, Sapanisertib can be used as a good drug for resisting premature aging (Example 2-Example 6).

[0019] In addition to its anti-aging effect in zebrafish met mutants, sapanisertib also has anti-aging effects on the physiological aging of wild-type zebrafish (Example 7) and the replicative aging of HFF cells (Example 8). Sapanisertib has good anti-aging activity and can be used as an active ingredient, alone or in combination with other pharmacologically active compounds and / or extracts, and can be made into anti-aging drugs or health products in various dosage forms (such as tablets, capsules, granules, powders, oral liquids, syrups or injections, etc.) with pharmaceutically acceptable carriers according to conventional methods in the pharmaceutical field, and then administered through appropriate routes, thereby effectively treating premature aging symptoms represented by Werner syndrome or delaying physiological aging. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 This is the overall flow chart of the experimental research of this technical solution.

[0021] Figure 2 These are images of the experimental results of premature aging of the intestine of the zebrafish met mutant in Example 1 (A. staining results of SA-β-gal in zebrafish embryos; B. quantitative analysis of SA-β-gal signal intensity in the intestine of zebrafish embryos).

[0022] Figure 3 The results of positional cloning of the mutagenic gene of the zebrafish met mutant in Example 1 (A. Gene map of the candidate region on chromosome 10; B. Schematic diagram of the genomic structure of the wrn gene; C. Schematic diagram of the domain structure of the Wrn protein in the wild type and mutant; D. The genome sequencing results show the mutation site in the wrn gene).

[0023] Figure 4 These are the experimental results of Example 1 in which overexpression of wrn rescued the cellular senescence of the met mutant (A. Schematic diagram of the construction of the wrn overexpression transgenic line and heat shock treatment; B. Stereo fluorescence images showing the expression of mCherry, indirectly reflecting the systemic overexpression of wrn after heat shock; C. Representative images of SA-β-Gal staining in the intestine at 8 dpf and quantitative analysis of its staining intensity, OE represents overexpression).

[0024] Figure 5 The research results of sapanisertib (Sapa) in Example 3 on improving cellular senescence of met mutants (A. Strategy diagram for anti-aging drug screening using zebrafish met mutants; B. Representative images of SA-β-Gal staining in the intestine at 8 dpf and quantitative analysis of its staining intensity; C. Quantitative PCR analysis of aging-related genes p21 and p53 in intestinal samples at 8 dpf).

[0025] Figure 6These are the experimental study results of Example 4 that sapanisertib (Sapa) extends the lifespan and health span of met mutants (A. The survival percentage of embryos in the wild type, control group and drug-treated group during the period from 0 dpf to 15 dpf; BD representative movement trajectories (B), movement distances (C) and movement speeds (D) of the wild type, control group and drug-treated group at 15 dpf, the yellow circle area represents the recording field, and the red line represents the swimming trajectory).

[0026] Figure 7 This is a study of the effect of sapanisertib (Sapa) in improving the fatty liver phenotype of met mutants in Example 5 (results of ORO staining and whole embryo in situ hybridization of cetp).

[0027] Figure 8 These are the research results of Example 6 on how sapanisertib reduces DNA damage in met mutants (A. Laser confocal image of γH2AX (red) in the intestine at 8 dpf; B. Quantitative analysis of γH2AX signal intensity).

[0028] Fig. 9 The experimental study results of sapanisertib (Sapa) in Example 7 on delaying the physiological aging of aged zebrafish (A. Representative images of SA-β-Gal staining in the intestine (upper figure) and fluorescent images of cell proliferation staining (lower figure, PCNA); B. Quantitative analysis of PCNA-positive cells in each villus space in the intestine; C. Representative images of SA-β-Gal staining in the renal medulla (upper figure) and fluorescent images of cell proliferation staining (lower figure, PCNA); D. Quantitative analysis of PCNA-positive cells in the renal medulla).

[0029] Fig.10 These are the experimental study results of Example 8 on sapanisertib (Sapa) delaying the replicative senescence of HFF cells (A. Representative images of SA-β-Gal staining in HFF cells; B. Quantitative analysis of SA-β-Gal staining in HFF cells; C. Representative images of cell proliferation staining (ki67) in HFF cells; D. Percentage of ki67-positive cells).

[0030] Fig.11 Comparison of the anti-aging effects of sapanisertib (Sapa) and rapamycin (Rapa) in Comparative Example 1 (A. Representative images of SA-β-Gal staining at 8 dpf and quantitative analysis of intestinal SA-β-Gal staining intensity, arrows indicate intestinal areas; B. Quantitative PCR analysis of aging-related genes p21 and p53 in intestinal samples at 8 dpf). DETAILED DESCRIPTION

[0031] The present invention is further described in detail below in conjunction with examples, but the embodiments of the present invention are not limited thereto. Unless otherwise specified, the technical means used in the following examples and experimental examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used can be obtained from commercial sources.

[0032] The overall flow chart of the experimental research of this technical solution is shown in Figure 1 . First, a zebrafish model of premature aging was established through ENU forward genetic screening. Second, high-throughput drug screening was performed using this model, and sapanisertib was found to be a promising anti-aging drug. In addition, the efficacy of sapanisertib was verified in physiologically aged zebrafish and replicatively aged human foreskin fibroblasts (HFF), demonstrating that sapanisertib can combat premature aging and natural aging.

[0033] Example 1: Animal Model of Progeria

[0034] (1) Zebrafish met mutants show cellular senescence in the intestine

[0035] In order to find premature aging mutants in zebrafish, the inventors conducted ENU (N-ethyl-N-nitrosourea) forward genetic mutagenesis screening. Senescence-associated β-galactosidase (SA-β-gal) is currently the most widely used marker for senescent cell detection and the most reliable and easy-to-detect aging indicator. The mutant zebrafish embryos were fixed at 8 days post fertilization (8dpf) and stained with SA-β-gal to assess cell senescence. Through large-scale screening, the inventors found a recessive mutant ( Figure 2 , the mutant is homozygous for the mutant gene, that is, both alleles are mutated; the gene is a recessive gene, and heterozygotes will not show premature aging phenotypes). The intestine is considered to be one of the first organs to age, which indicates that the mutant has a premature aging phenotype.

[0036] Among them, the method of β-galactosidase staining is as follows (senescence-related β-galactosidase is the most widely used marker for senescent cell detection, known as the "gold standard" for senescent cell detection, and is the most reliable and easy-to-detect senescence indicator):

[0037] The cell senescence β-galactosidase staining kit was purchased from Biotech Co., Ltd. (C0602). The main staining steps of zebrafish embryos are as follows: embryos were fixed with 4% PFA overnight at 4°C; washed 3 times with 1×PBT, 20 minutes each time; fixed with fixative at room temperature for 15 minutes, and then freshly prepared β-galactosidase staining working solution was added and stained at 37°C overnight (the staining solution preparation method was: β-galactosidase staining solution A 10μl, β-galactosidase staining solution B 10μl, β-galactosidase staining solution C 930μl, X-Gal solution 50μl); images were collected with a SteREO Discovery V20 microscope, and the staining results were analyzed using ImageJ software. The main staining steps for adult zebrafish tissue sections are as follows: tissue samples were fixed with 4% PFA overnight at 4°C, washed, dehydrated with 30% sucrose (Sangon Biotech, Shanghai) overnight and embedded in OCT (Tissue Tek, Sakura). The tissue was cut into 10 μm thickness using a freezing microtome, and the SA-β-gal staining procedure of the sections was the same as that of zebrafish embryos, but the staining time was different. The kidney cord was incubated at 37°C for 16 hours and the intestine for 3 hours. Finally, the slides were washed with PBS and stained with nuclear fast red staining solution (C0151, Beyotime) for 5 minutes before taking pictures.

[0038] (2) The aging phenotype in zebrafish met mutants is caused by mutations in the wrn gene

[0039] To identify the mutated gene that causes intestinal aging in met mutants, the inventors used positional cloning technology to narrow the mutation region to 0.19Mb ( Figure 3 A). The method of positional cloning is as follows: First, the met mutant is hybridized with the SJD strain with simple sequence length polymorphism (SSLP) to obtain the polymorphic F1 generation. When the F1 reaches adulthood, the heterozygotes carrying the met mutant are screened out, and then these heterozygotes are mated to obtain the F2 generation. Finally, by collecting homozygous met mutants in the F2 generation on a large scale for positional cloning, after analyzing the recombination of 1305 mutant embryos, the mutation region was narrowed down to 0.19Mb. After exon and genome sequencing analysis of the five protein-coding genes in this region, it was found that the 50th base pair of exon 5 of the met gene carries a T to A mutation, which causes the translation of the encoded protein to terminate prematurely.

[0040] After performing exon and genome sequencing analysis on the five protein-coding genes in the region, the inventors found that the 50th base pair of exon 5 of the wrn (WRN RecQ like helicase, Gene ID: 569495) gene carried a T to A mutation, which resulted in premature termination of the translation of the encoded protein ( Figure 3 BD). To further verify whether the aging phenotype is caused by the wrn mutation, the inventors used the transgenic line Tg (hsp70l:wrn-HA-p2A-mCherry) to perform a rescue experiment. In this transgenic line, wrn is overexpressed throughout the body after heat shock ( Figure 4 A, B). The results showed that wrn overexpression can rescue cell senescence in met mutants ( Figure 4 C) The above results indicate that the cell senescence phenotype in met mutants is indeed caused by the wrn gene mutation.

[0041] (3) Zebrafish premature aging model

[0042] Due to the long lifespan of vertebrates, the current screening of anti-aging drugs mainly relies on in vitro models or invertebrate models. However, in vitro models cannot fully simulate the complex physiological environment in organisms, while invertebrate models lack key organs and systems in the human aging process. Due to the lack of animal models for drug screening, it is difficult to screen out effective anti-aging drugs.

[0043] Zebrafish has become an ideal model for high-throughput drug screening due to its advantages such as strong reproductive capacity, small size and low breeding cost, as well as the fact that 82% of human pathogenic genes have homologous genes in zebrafish. However, the zebrafish's lifespan of up to 5 years poses a huge challenge to the screening of anti-aging drugs. Therefore, obtaining a zebrafish premature aging model is crucial for large-scale screening of anti-aging drugs. This protocol uses the zebrafish premature aging model as a model for drug screening. The premature aging phenotype is mainly manifested in: shortened lifespan and decreased motor ability in the early stages of development, as well as changes in the expression of aging markers, such as increased intestinal SA-β-gal expression, upregulated expression of p21 and p53, and increased DNA damage.

[0044] Through N-ethyl-N-nitrosourea (ENU) forward genetic screening, the inventors identified a zebrafish premature aging mutant and named it meteor (met). Through positional cloning and gene sequencing, it was found that the mutating gene of the met mutant is wrn. Mutations in the human WRN gene are associated with Werner syndrome (WS) (WRN gene mutations can lead to the occurrence of WS), which is characterized by accelerated aging of patients and has become an ideal model for studying human aging. The inactivation of the wrn gene in the zebrafish met mutant can be used to simulate aging symptoms, especially WS. Therefore, the zebrafish met mutant can be used to screen anti-aging drugs, especially for the screening of drugs for the treatment of WS.

[0045] The zebrafish met mutant used for drug screening in this scheme is now stored in the Center for Developmental Biology and Regenerative Medicine of Southwest University. The applicant promises to release the above zebrafish met mutant genetic resources to the public within 20 years from the date of application.

[0046] Example 2: Drug Screening

[0047] The drug screening process was as follows: The screening library contained a total of 2442 compounds, including a custom library (L2000-Z481077, Selleck, TX, USA) and an FDA-approved drug library (HY-L022, MCE, NJ, USA). The main process of drug screening was as follows: 6 4dpf met mutant embryos were distributed into the wells of a 24-well plate, and 0.5ml egg water was added to each well, with a final drug concentration of 10μmol / L. The control group was exposed to DMSO or water according to the solvent used to dissolve the drug in the screening library. Then, the culture plate was incubated at 28.5℃ for 4 days. 8dpf embryos were fixed with 4% PFA at 4℃ overnight, and intestinal aging was assessed using SA-β-gal staining.

[0048] Example 3: Study on the improving effect of sapanisertib on cell senescence of met mutants

[0049] The method for treating zebrafish embryos with sapanisertib is as follows: the treatment group is continuously exposed to sapanisertib (Cat. No. S2811, Selleckchem) at 4-8 dpf, with a final concentration of 2 μM; the control group is treated with DMSO.

[0050] The experimental method of β-galactosidase staining is shown in Example 1. Real-time quantitative PCR (q-PCR) was performed using the NucleoZOL kit (MACHEREY-NAGEL) to extract total RNA from zebrafish intestinal tissue at 8 dpf, and reverse transcribed into cDNA using the OmniScript Reverse Transcription kit (QIAGEN). The kit used for qPCR was FastStart Universal SYBR Green Master (Roche), with actb2 as the internal reference, and the CT value of the target gene was measured by 2 -ΔΔCT The primers for p21 gene are: ATGCAGCTCCAGACAGATGA (SEQ ID NO.1, forward), CGCAAACAGACCAACATCAC (SEQ ID NO.2, reverse); the primers for p53 gene are: CCCGGATGGAGATAACTTG (SEQ ID NO.3, forward), CACAGTTGTCCATTCAGCAC (SEQ ID NO.4, reverse); the primers for actb2 gene are: GAAATTGCCGCACTGGTTGT (SEQ ID NO.5, forward); AGCCTCATCACCAACGTAGC (SEQ ID NO.6, reverse).

[0051] Since zebrafish met mutants show rapid aging at 8 dpf, it is possible to screen high-throughput anti-aging drugs in vertebrates. Therefore, the inventors used the SA-β-gal assay to screen large-scale anti-aging drugs in zebrafish met mutants ( Figure 5 A). The results showed that sapanisertib can effectively improve the senescence of intestinal cells in met mutants. SA-β-gal staining results showed that compared with wild-type embryos, a large number of blue signals appeared in the intestines of met mutants, while the blue signals in mutants treated with sapanisertib were significantly reduced, indicating that sapanisertib can effectively delay cell senescence ( Figure 5 B). In addition, p21 and p53 are also marker genes of cell senescence. Quantitative PCR results showed that the expression of p21 and p53 was significantly upregulated in the intestine of the mutant, but was significantly inhibited after sapanisertib treatment, further demonstrating that sapanisertib can delay cell senescence ( Figure 5 C) It can be seen that through drug screening, it was found that sapanisertib can improve the cellular senescence of met mutants.

[0052] Sapanisertib is an orally active small molecule drug, also known as TAK-228, INK-128 or MLN0128. Clinical studies of sapanisertib are mainly focused on the treatment of various types of tumors, including breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, malignant melanoma, etc. At present, there are no reports on the use of sapanisertib in the field of anti-aging. Its structural formula is shown in formula (1), and its CAS number is 1224844-38-5.

[0053]

[0054] Example 4: Effects of sapanisertib on lifespan and health status of met mutants

[0055] When testing mobility, a single zebrafish embryo was first transferred to a 12-well plate containing 1 ml of egg water, and the embryo was allowed to adapt to the environment for 5 minutes, and then its behavior was recorded for 5 minutes. All data were analyzed using the Ethovision XT15 animal tracking system (Noldus), and the movement distance and movement speed were calculated. In the test of life span and mobility, the treatment group was continuously exposed to sapanisertib at 4-15 dpf, with a final drug concentration of 2 μM. During the test, no drug removal was performed.

[0056] In addition to cellular senescence, another obvious feature of WS patients is a shorter lifespan. Similarly, the inventors found that met mutants had a significantly shortened lifespan, while sapanisertib treatment extended their lifespan ( Figure 6 A). Swimming ability is the main indicator of zebrafish health status. The swimming ability of met mutants was significantly reduced at 15dpf. However, after sapanisertib treatment, the swimming ability of met mutants could be partially restored ( Figure 6 BD). The above results show that sapanisertib has the function of extending the lifespan and healthy lifespan of met mutants. It can be seen that sapanisertib can be used to improve the lifespan and health status of premature aging individuals.

[0057] Example 5: Study on the improving effect of sapanisertib on the fatty liver phenotype of met mutants

[0058] Oil Red O (ORO) reagent was purchased from Sigma (O1391). The main experimental steps are as follows: embryos were fixed with 4% PFA overnight at 4°C; washed 3 times with 1×PBT for 5 minutes each time; washed 3 times with 60% isopropanol for 5 minutes each time; ORO working solution was prepared at 100% isopropanol: ddH2O = 3:2, and 500ul working solution was added to each tube of embryos; protected from light, stained at 37°C for 30 minutes; after incubation, washed 3 times with ddH2O for 5 minutes each time, and photographed under a SteREO Discovery V20 microscope. In the above experimental process, the treatment group was continuously exposed to sapanisertib at 4-8dpf, with a final drug concentration of 2μM, and the 8dpf embryos were subjected to staining experiments.

[0059] Studies have shown that WS patients have a significantly increased risk of developing fatty liver. The results of oil red O (ORO) lipid staining and whole embryo in situ hybridization for the fatty liver marker cetp showed that there was more lipid accumulation in the liver of met mutants, while sapanisertib treatment significantly reduced the lipid in the liver ( Figure 7 ).

[0060] Example 6: Study on the effect of sapanisertib on reducing DNA damage in met mutants

[0061] The sapanisertib drug treatment was the same as in Example 3 (the treatment group was continuously exposed to sapanisertib at 4-8 dpf, with a final concentration of 2 μM), and the experimental study was conducted on 8 dpf embryos. The primary antibodies used include: Dendra2 (1:500 dilution, catalog number TA180094, purchased from Origene), γH2AX (1:500 dilution, catalog number GTX127342, purchased from Gene Tex), pS6 (1:500 dilution, catalog number 2215, purchased from Cell Signaling), p-4EBP (1:500 dilution, catalog number 2855, purchased from Cell Signaling) and p-Akt S473 (1:100 dilution, catalog number 9271, purchased from Cell Signaling); the secondary antibodies used include donkey anti-mouse IgG Alexa fluor 488-conjugated, donkey anti-rabbit Alexafluor 568-conjugated and donkey anti-rabbit IgG Alexa fluor 647-conjugated, all with a dilution ratio of 1:1000, purchased from Invitrogen. The main experimental steps are as follows: embryos were fixed with 4% PFA overnight at 4°C; washed with 1×PBT 3 times, 10 minutes each time; rinsed with 1×PT 5 times, 40 minutes each time after peeling; blocked with PBTN in a 4°C cold storage for 2 hours; diluted the corresponding primary antibody with PBTN, added 100ul antibody working solution to each tube of embryos, and kept at 4°C overnight; recovered the primary antibody and rinsed with 1×PT 5 times, 40 minutes each time; diluted the secondary antibody (1:2000) with PBTN, added 200ul secondary antibody working solution to each tube of embryos, and kept at 4°C overnight. Rinse with 1×PT 5 times, 40 minutes each time, and take pictures under LSM780 or LSM880 confocal microscope after DAPI staining.

[0062] Accumulation of DNA damage is considered to be one of the important causes of aging, and reducing DNA damage is a key strategy to delay aging. In order to evaluate the damage of endogenous DNA in met mutants, we detected the DNA damage marker γH2AX. The results showed that there was almost no γH2AX signal in wild-type embryos, while the number of γH2AX-positive cells in the intestine of met mutants increased significantly, but the γH2AX level decreased significantly after sapanisertib treatment, indicating that drug treatment reduced the accumulation of DNA damage ( Figure 8 ). Therefore, sapanisertib can reduce DNA damage in met mutants.

[0063] Example 7: Research results on sapanisertib alleviating physiological aging in aged zebrafish

[0064] Sapanisertib treatment of aged zebrafish was performed as follows: Three groups of wild-type zebrafish (AB strain) were used in this study, and the fish were divided into two categories: young (6 months old) and old (3 years old). The young and old control groups were treated with DMSO, while the old sapanisertib group was treated with 500nM sapanisertib. Treatment method: Treatment was performed 6 days a week, 10 hours a day in dark conditions with sapanisertib / DMSO treatment and 14 hours a day in light conditions with system water treatment. The total duration of sapanisertib was four months.

[0065] To further investigate whether sapanisertib can delay physiological aging, the inventors analyzed the intestines and renal medulla of old wild-type zebrafish treated with sapanisertib. Compared with young zebrafish (6 months old), old zebrafish (3 years old) showed obvious SA-β-Gal activity in the intestines and renal medulla, and this phenomenon was improved after sapanisertib treatment ( Fig. 9 A, C). Similarly, sapanisertib treatment increased the proliferation of cells in the intestine and kidney medulla of aged zebrafish ( Fig. 9 AD).

[0066] Example 8: Sapanisertib reduces replicative senescence of HFF cells

[0067] HFF cells (Human Foreskin Fibroblasts) were provided by the Cell Bank of the Chinese Academy of Sciences. The cells were cultured in DMEM (Gibco) medium containing 15% inactivated fetal bovine serum (FBS, Gibco). The culture environment was a constant temperature of 37°C, 5% CO2 / 95% air. 100U / ml penicillin and 0.1mg / ml streptomycin were additionally added to the culture medium to prevent contamination. After the cells reached confluence, a solution containing 0.25% trypsin and 0.02% EDTA was used to separate the cells from the culture container and passage them. HFF cells were divided into a control group and a treatment group. Starting from the 20th generation (P20), the treatment group was continuously treated with 5nM sapanisertib, and the control group was treated with the corresponding solvent (DMSO).

[0068] HFF cells are one of the recognized models for studying cell senescence. The study found that when HFF cells were passed to the 20th generation (P20), the SA-β-Gal signal remained weak, indicating that the cells had not undergone significant senescence; when HFF cells were passed to the 30th generation (P30), a large number of SA-β-Gal signals appeared, and this phenomenon was reversed after treatment with sapanisertib ( Fig.10 A, B). In addition, sapanisertib increased the proliferation rate of HFF cells at passage 30 ( Fig.10 C,D).

[0069] Based on the above experimental results, the following conclusions can be drawn: In addition to its anti-aging effect in zebrafish met mutants, sapanisertib also has anti-aging effects on the physiological aging of wild-type zebrafish and the replicative aging of HFF cells. Sapanisertib has good anti-aging activity and can be used as an active ingredient, alone or in combination with other pharmacologically active compounds and / or extracts, and can be made into anti-aging drugs or health products in various dosage forms (such as tablets, capsules, granules, powders, oral liquids, syrups or injections, etc.) with pharmaceutically acceptable carriers according to conventional methods in the pharmaceutical field, and then administered through appropriate routes, thereby effectively treating WS or delaying physiological aging.

[0070] Comparative Example 1

[0071] In Example 2, the inventors tried to detect the anti-aging activity of 2442 compounds in the premature aging animal model of zebrafish met mutants, and only found that sapanisertib had a relatively prominent anti-aging activity. It can be seen that it is difficult to screen for drugs with anti-aging functions. In addition, the inventors also tried the anti-aging effect of the known anti-aging drug rapamycin (rapamycin, the structural formula is shown in formula (2)) in this model. The results showed that although rapamycin can alleviate the aging phenotype in this model, its anti-aging effect is not as ideal as sapanisertib, which further proves the superior anti-aging effect of sapanisertib ( Fig.11 , see Example 3 for specific experimental methods, sapa represents sapanisertib, and rapa represents rapamycin).

[0072]

[0073] The above is only an embodiment of the present invention, and the common knowledge such as the known specific technical solutions and / or characteristics in the solution is not described in detail here. It should be pointed out that for those skilled in the art, without departing from the technical solution of the present invention, several modifications and improvements can be made, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicality of the patent. The scope of protection required by this application shall be based on the content of its claims, and the specific implementation methods and other records in the specification can be used to interpret the content of the claims.

Claims

1. Application of sapanisertib in the preparation of anti-aging drugs.

2. The use of sapanisertib in the preparation of anti-aging drugs according to claim 1, characterized in that: The anti-aging drug is a drug that resists physiological aging or cell replicative aging.

3. The use of sapanisertib in the preparation of anti-aging drugs according to claim 1, characterized in that: The anti-aging drug is a drug for resisting premature aging.

4. The use of sapanisertib in the preparation of anti-aging drugs according to claim 3, characterized in that: Drugs that fight premature aging are drugs used to treat Werner syndrome.

5. The use of sapanisertib in the preparation of anti-aging drugs according to claim 4, characterized in that: Sapanisertib is used to improve lifespan and exercise capacity in individuals with progeria.

6. The use of sapanisertib in the preparation of anti-aging drugs according to claim 4, characterized in that: Sapanisertib is used to reduce the expression level of β-galactosidase, as well as the expression levels of the p21 gene and the p53 gene.

7. The use of sapanisertib in the preparation of anti-aging drugs according to claim 4, characterized in that: Sapanisertib is used to reduce the risk of fatty liver disease in individuals with progeria.

8. The use of sapanisertib in the preparation of anti-aging drugs according to claim 4, characterized in that: Sapanisertib is used to reduce DNA damage in individuals with progeria.

9. The use of sapanisertib according to any one of claims 1 to 8 in the preparation of anti-aging drugs, characterized in that: Sapanisertib is intended for use alone or in combination with other pharmacologically active compounds and / or extracts.

10. The use of sapanisertib according to any one of claims 1 to 8 in the preparation of anti-aging drugs, characterized in that: Sapanisertib and a pharmaceutically acceptable carrier are prepared into tablets, capsules, granules, powders, oral solutions, syrups or injections.